Non alcoholic fatty liver disease

CPD Bulletin Clinical Biochemistry

Volumn 9, Issue 2, 2008, Pages 47-53

  Oben, Jude A ^a,b   Nikolopoulos, Antonis ^a   Paulon, Emma ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Guy's and St Thomas' Hospitals   (United Kingdom)

Author keywords

Alanine aminotransferase; Gamma glutamyltranferase; Hepatosteatosis (fatty liver); Obesity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; METFORMIN; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; RIMONABANT; SIBUTRAMINE; TAUROURSODEOXYCHOLIC ACID; TETRAHYDROLIPSTATIN; TROGLITAZONE;

CHRONIC LIVER DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; FATTY LIVER; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MOOD; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; SIDE EFFECT; STEATOSIS;

EID: 64549128649     PISSN: 13678930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Ludwig J, Viggiano TR, Mcgill DB et al. Nonalcoholic Steatohepatitis: Mayo Clinic Experiences with a Hitherto Unnamed Disease. Mayo Clin Proc 1980; 55: 434-82.
2. Falck-Ytter Y, Younossi ZM, Marchesini G et al. Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. Semin Liver Dis 2001; 21: 17-26.
3. Bugianesi E, Leone N, Vanni E et al. Expanding the Natural History of Nonalcoholic Steatohepatitis: From Cryptogenic Cirrhosis to Hepatocellular Carcinoma. Gastroenterology 2002; 123: 134-40.
4. Powell EE, Cooksley WG, Hanson R et al. The Natural History of Nonalcoholic Steatohepatitis: A Follow-Up Study of Forty-Two Patients for Up To 21 Years. Hepatology 1990; 11: 74-80.
5. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study. Hepatology 2005; 42: 44-52.
6. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and Risk Factors for Hepatic Statosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
7. Clark JM, Brancati FL & Diehl AM. The Prevalence and Etiology of Elevated Aminotransferase Levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
8. Ruhl CE & Everhart JE. Determinants of the Association of Overweight with Elevated Serum Alanine Aminotransferase Activity in the United States. Gastroenterology 2003; 124: 71-9.
9. Szczepaniak LS, Nurenberg P, Leonard D et al. Magnetic Resonance Spectroscopy to Measure Hepatic Triglyceride Content: Prevalence of Hepatic Steatosis in the General Population. Am J Physiol Endocrinol Metab 2005; 288: E462-8.
10. Wanless IR & Lentz JS. Fatty Liver Hepatitis (Steatohepatitis) and Obesity: An Autopsy Study with Analysis of Risk Factors. Hepatology 1990; 12: 1106-10.
11. Underwood-Ground K. Prevalence of Fatty Liver in Healthy Male Adults Accidentally Killed. Aviat Space Environ Med 1984; 55: 59-61.
12. Yu AS & Keeffe EB. Nonalcoholic Fatty Liver Disease. Rev Gastroenterol Disord 2002; 2: 11-9.
13. Bugianesi E, Gastaldelli A, Vanni E et al. Insulin Resistance in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease: Sites and Mechanisms. Diabetologia 2005; 48: 634-42.
14. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome. Diabetes 2001; 50: 1844-50.
15. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome. Hepatology 2003; 37: 917-23.
16. Pratt DS & Kaplan MM. Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 2002; 342: 1266-71.
17. Mokdad AH, Ford ES, Bowman BA et al. The Continuing Increase of Diabetes in the US. Diabetes Care 2001; 24: 412.
18. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors. Jama 2003; 289: 76-9.
19. Michael C. Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of The American Gastroenterological Association 2004; 2: 1048-58.
20. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-Term Follow-up of Patients with Nafld and Elevated Liver Enzymes. Hepatology 2006; 44: 865-73.
21. Adams LA, Lymp JF, St Sauver J et al. The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology 2005; 129: 113-21.
22. Villanova N, Moscatiello S, Ramilli S et al. Endothelial Dysfunction and Cardiovascular Risk Profile in Nonalcoholic Fatty Liver Disease. Hepatology 2005; 42: 473-80.
23. El-Serag HB, Tran T & Everhart JE. Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma. Gastroenterology 2004; 126: 460-8.
24. Mccullough AJ. Update on Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2002; 34: 255-62.
25. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of Hepatic Steatosis in an Urban Population in the United States: Impact of Ethnicity. Hepatology 2004; 40: 1387-95.
26. Bacon Farahvash, Janney & Neuschwander T. Nonalcoholic Steatohepatitis: An Expanded Clinical Entity. Nonalcoholic Steatohepatitis: An Expanded Clinical Entity 1994; 107: 1103-9.
27. Brunt EM. Nonalcoholic Steatohepatitis: Definition and Pathology. Semin Liver Dis 2001; 21: 3-16.
28. Adams LA, Lindor KD & Angulo P. The Prevalence of Autoantibodies and Autoimmune Hepatitis in Patients with Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2004; 99: 1316-20.
29. Caturelli E, Squillante MM, Andriulli A et al. Hypoechoic Lesions in the 'Bright Liver': A Reliable Indicator of Fatty Change. A Prospective Study. J Gastroenterol Hepatol 1992; 7: 469-72.
30. Saadeh S, Younossi ZM, Remer EM et al. The Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 745-50.
31. Skelly MM, James PD & Ryder SD. Findings on Liver Biopsy to Investigate Abnormal Liver Function Tests in the Absence of Diagnostic Serology. J Hepatol 2001; 35: 195-9.
32. Bravo AA, Sheth SG & Chopra S. Liver Biopsy. N Engl J Med 2001; 344: 495-500.
33. Ratziu V, Charlotte F, Heurtier A et al. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. Gastroenterology 2005; 128: 1898-906.
34. Kettaneh A, Marcellin P, Douvin C et al. Features Associated with Success Rate and Performance of Fibroscan Measurements for the Diagnosis of Cirrhosis in HCV Patients: A Prospective Study of 935 Patients. J Hepatol 2007; 46: 628-34.
35. Guha IN, Parkes J, Roderick P et al. Noninvasive Markers of Fibrosis in Nonalcoholic Fatty Liver Disease: Validating the European Liver Fibrosis Panel and Exploring Simple Markers. Hepatology 2008; 47: 455-60.
36. Brunt, E. M. Nonalcoholic Steatohepatitis: Pathologic Features and Differential Diagnosis. Semin Diagn Pathol 2005; 22: 330-8.
37. Brunt EM. Pathology of Fatty Liver Disease. Mod Pathol 2007; 20 Suppl 1, S40-8.81.
38. Kleiner DE, Brunt EM, Van Natta M et al. Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology 2005; 41: 1313-21.
39. Day CP & James OF. Steatohepatitis: A Tale of Two "Hits"? Gastroenterology 1998; 114: 842-5.
40. Harrison SA & Di Bisceglie AM. Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease. Drugs 2003; 63: 2379-94.
41. Hui JM, Hodge A, Farrell GC et al. Beyond Insulin Resistance in Nash: TN-Alpha or Adiponectin? Hepatology 2004; 40: 46-54.
42. Kamada Y, Matsumoto H, Tamura S et al. Hypoadiponectinemia Accelerates Hepatic Tumor Formation in a Nonalcoholic Steatohepatitis Mouse Model. J Hepatology 2007; 7: 556-564.
43. Tilg H & Diehl AM. Cytokines in Alcoholic and Nonalcoholic Steatohepatitis. N Engl J Med 2000; 343: 1467-76.
44. Letteron P, Fromenty B, Terris B et al. Acute and Chronic Hepatic Steatosis Lead to in-vivo Lipid Peroxidation in Mice. J Hepatol 1996; 24: 200-8.
45. Yamaguchi K, Yang L, Mccall S et al. Inhibiting Triglyceride Synthesis Improves Hepatic Steatosis but Exacerbates Liver Damage and Fibrosis in Obese Mice with Nonalcoholic Steatohepatitis. Hepatology 2007; 45: 1366-74.
46. Nielsen S, Guo Z, Johnson CM et al. Splanchnic Lipolysis in Human Obesity. J Clin Invest 2004; 113: 1582-8.
47. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of Fatty Acids Stored in Liver and Secreted Via Lipoproteins in Patients with Nonalcoholic Fatty Liver Disease. J Clin Invest 2005; 115: 1343-51.
48. Kechagias S, Ernersson A, Dahlqvist O et al. Fast-Food-Based Hyper-Alimentation Can Induce Rapid And Profound Elevation Of Serum Alanine Aminotransferase In Healthy Subjects. Gut 2008; 57: 649-54.
49. Noren B, Dahlqvist O, Lundberg P et al. Separation of Advanced from Mild Fibrosis in Diffuse Liver Disease Using (31) P Magnetic Resonance Spectroscopy. Eur J Radiol 2008; 66: 313-20.
50. Scribner KB, Pawlak DB & Ludwig DS. Hepatic Steatosis and Increased Adiposity in Mice Consuming Rapidly Vs. Slowly Absorbed Carbohydrate. Obesity (Silver Spring) 2007; 15: 2190-9.
51. Schwarz JM, Linfoot P, Dare D et al. Hepatic De Novo Lipogenesis in Normoinsulinemic and Hyperinsulinemic Subjects Consuming High-Fat, Low-Carbohydrate and Low-Fat, High-Carbohydrate Isoenergetic Diets. Am J Clin Nutr 2003; 77: 43-50.
52. Valtuena S, Pellegrini N, Ardigo D et al. Dietary Glycemic Index and Liver Steatosis. Am J Clin Nutr 2006; 84: 136-42; Quiz 268-9.
53. Nelson JE, Bhattacharya R, Lindor KD et al. HFE C282y Mutations are Associated with Advanced Hepatic Fibrosis in Caucasians with Nonalcoholic Steatohepatitis. Hepatology 2007; 46: 723-9.
54. George DK, Goldwurm S, Macdonald GA et al. Increased Hepatic Iron Concentration in Nonalcoholic Steatohepatitis is Associated with Increased Fibrosis. Gastroenterology 1998; 114: 311-8.
55. Cai D, Yuan M, Frantz DF et al. Local and Systemic Insulin Resistance Resulting from Hepatic Activation of Ikk-Beta and Nf-Kappab. Nat Med 2005; 11: 183-90.
56. Kamada Y, Matsumoto H, Tamura S et al. Hypoadiponectinemia Accelerates Hepatic Tumor Formation in a Nonalcoholic Steatohepatitis Mouse Model. J Hepatol 2007; 47: 556-64.
57. Fromenty B & Pessayre D. Inhibition of Mitochondrial Beta-Oxidation as a Mechanism Of Hepatotoxicity. Pharmacol Ther 1995; 67: 101-54.
58. Cope K, Risby T & Diehl AM. Increased Gastrointestinal Ethanol Production in Obese Mice: Implications for Fatty Liver Disease Pathogenesis. Gastroenterology 2000; 119: 1340-7.
59. Nair S, Cope K, Risby TH et al. Obesity and Female Gender Increase Breath Ethanol Concentration: Potential Implications for the Pathogenesis of Nonalcoholic Steatohepatitis. Am J Gastroenterol 2001; 96: 1200-4.
60. Hezode C, Roudot-Thoraval F, Nguyen S et al. Daily Cannabis Smoking as a Risk Factor for Progression of Fibrosis in Chronic Hepatitis C. Hepatology 2005; 42: 63-71.
61. Hezode C, Zafrani ES, Roudot-Thoraval F et al. Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients with Chronic Hepatitis C. Gastroenterology 2008; 134: 432-9.
62. Osei-Hyiaman D, Depetrillo M, Pacher P et al. Endocannabinoid Activation at Hepatic Cb1 Receptors Stimulates Fatty Acid Synthesis and Contributest Diet-Induced Obesity. J Clin Invest 2005; 115: 1298-305.
63. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R et al. Endocannabinoid Receptor Cb2 in Nonalcoholic Fatty Liver Disease. Liver Int 2007; 27: 215-9.
64. Julien B, Grenard P, Teixeira-Clerc F et al. Antifibrogenic Role of the Cannabinoid Receptor CB2 in the Liver. Gastroenterology 2005; 128: 742-55.
65. Oben JA, Roskams T, Yang S et al. Norepinephrine Induces Hepatic Fibrogenesis in Leptin Deficient Ob/Ob Mice. Biochem Biophys Res Commun 2003; 308: 284-92.
66. Oben JA, Roskams T, Yang S et al. Hepatic Fibrogenesis Requires Sympathetic Neurotransmitters. Gut 2004; 53: 438-45.
67. Hirose A, Ono M, Saibara T et al. Angiotensin Ii Type 1 Receptor Blocker Inhibits Fibrosis in Rat Nonalcoholic Steatohepatitis. Hepatology 2007; 45: 1375-81.
68. Clark JM, Alkhuraishi ARA, Solga SF et al. Gastric Bypass Improves Liver Histology in Patients with Non-Alcoholic Fatty Liver Disease. Obesity Res 2005; 13: 1180-6.
69. Klein S, Mittendorfer B, Eagon JC et al. Gastric Bypass Surgery Improves Metabolic and Hepatic Abnormalities Associated with Nonalcoholic Fatty Liver Disease. Gastroenterology 2006; 130: 1564-1572.
70. Ueno T, Sugawara H, Sujaku K et al. Therapeutic Effects of Restricted Diet and Exercise in Obese Patients with Fatty Liver. J Hepatol 1997; 27: 103-7.
71. Capron JP, Delamarre J, Dupas JL et al. Fasting in Obesity: Another Cause of Liver Injury With Alcoholic Hyaline? Dig Dis Sci 1982; 27: 265-8.
72. Clark JM. Weight Loss as a Treatment for Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2006; 40: S39-43.
73. Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant Reduces Obesity-Associated Hepatic Steatosis and Features of Metabolic Syndrome in Obese Zucker Fa/Fa Rats. Hepatology 2007; 46: 122-9.
74. Matias I & Di Marzo V. Endocannabinoids and the Control of Energy Balance. Trends Endocrinol Metab 2007; 18: 27-37.
75. Lin HZ, Yang SQ, Kujhada F et al. Metformin Reverses Nonalcoholic Fatty Liver Disease in Obese Leptin-Deficient Mice. Nat Med 2000; 6: 998-1003.
76. Cleasby ME, Dzamko N, Hegarty BD et al. Metformin Prevents the Development of Acute Lipid-Induced Insulin Resistance in the Rat through Altered Hepatic Signalling Mechanisms. Diabetes 2004; 53: 3258-66.
77. Nair S, Diehl AM, Wiseman M et al. Metformin in the Treatment of Non-Alcoholic Steatohepatitis: A Pilot Open Label Trial. Aliment Pharmacol Ther 2004; 20: 23-8.
78. Caldwell SH, Hespenheide EE, Redick JA et al. A Pilot Study of a Thiazolidinedione, Troglitazone, in Nonalcoholic Steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
79. Belfort R, Harrison SA, Brown K et al. A Placebo-Controlled Trial of Pioglitazone i Subjects wth Nonalcoholic Steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
80. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA et al. A Pilot Study of Atorvastatin Treatment in Dyslipemid, Non-Alcoholic Fatty Liver Patients. Alimentary Pharmacology & Therapeutics 2006; 23: 1643-1647.
81. Browning JD. Statins and Hepatic Steatosis: Perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-71.
82. Sanyal AJ, Mofrad PS, Contos MJ et al. A Pilot Study of Vitamin E Versus Vitamin E And Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
83. Clark JM & Brancati FL. Negative Trials in Nonalcoholic Steatohepatitis: Why They Happen and What They Teach Us. Hepatology 2004; 39: 602-3.
84. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial. Hepatology 2004; 39: 770-8.
85. Solga SF & Diehl AM. Non-Alcoholic Fatty Liver Disease: Lumen-Liver Interactions and Possible Role for Probiotics. J Hepatol 2003; 38: 681-7.
86. Yokohama S, Yoneda M, Haneda M et al. Therapeutic Efficacy of an Angiotensin Ii Receptor Antagonist in Patients with Nonalcoholic Steatohepatitis. Hepatology 2004; 40: 1222-5.
87. Oben JA, Roskams T, Yang S et al. Sympathetic Nervous System Inhibition Increases Hepatic Progenitors and Reduces Liver Injury. Hepatology 2003; 38: 664-73.